Morgan Stanley Cuts Camtek to Underweight Ahead of November Print

CAMT heads into its November 10 earnings report carrying a fresh downgrade, a 32% one-month share price decline, and short interest running above 7% of free float.

The most consequential move this week came from Morgan Stanley. Shane Brett downgraded CAMT to Underweight from Equal-Weight on November 2, cutting his price target to $126 from $152. That is a sharp shift in posture from a bellwether firm, and the timing, one week before the Q3 print, gives it added weight. The broader analyst picture is one of steady target erosion. Needham trimmed to $170 from $190 in mid-October while keeping Buy, and B. Riley followed with a cut to $166 from $200. The consensus rating has drifted to Hold, and the mean target of $170 sits well above the current price of $112.37, though that gap reflects how far the stock has fallen rather than any fresh optimism on the Street. The Morgan Stanley Underweight is now the clearest statement of near-term concern.

Short positioning tells a nuanced story. At 7.4% of free float, short interest is meaningful but not extreme, and it has actually eased slightly over the past month, down around 8%. The ORTEX short score nonetheless remains elevated at 72.6, placing CAMT in the third percentile for short score rank across the universe. The borrow market has loosened considerably: cost to borrow has fallen 35% on the week to 3.0%, and availability has improved to 64%, well above the 0.2% trough seen earlier in the year when the lending pool was essentially closed. That combination of declining shorts and cheaper, more available borrow suggests the short community is not pressing new bets aggressively into earnings, but the score reflects a market that still treats this as a high-conviction short target relative to peers.

Options positioning is notably calm given the surrounding turbulence. The put/call ratio of 0.69 sits almost exactly in line with its 20-day average of 0.70, a z-score of minus 0.31, and the ratio has barely moved over the past month. The 52-week range runs from 0.37 to 1.18, so current positioning is neither defensive nor particularly bullish. For a stock down 13% on the week and 32% over the past month, the absence of a protective put bid stands out. Either options traders are comfortable with existing hedges, or they are not bracing for further near-term downside at current levels.

Valuation has re-rated sharply. The trailing P/E has compressed from roughly 36 to 23 over the past 30 days, and price-to-book has fallen 3.2 turns in the same period to just above 5. EV/EBITDA has held more steadily near 19. The factor picture is mixed: forward earnings estimate momentum ranks in the 86th percentile on a 12-month basis, and 90-day EPS momentum scores at 63, suggesting analysts have not abandoned the long-term revenue case. But EPS surprise ranks in just the 20th percentile, and analyst recommendation differential is at the fourth percentile, capturing how much the sell-side skew has shifted. The bear case centres on CAMT's heavy reliance on its Hawk and Eagle G5 tools in a cyclical market with concentrated Asian exposure; the bull case rests on advanced packaging demand and the Visual Layer acquisition extending its detection capabilities.

Ownership concentration is notable. Priortech holds 20.6% of shares and Chroma ATE holds 16.8%, together accounting for more than a third of the company before any institutional count. Among funds, Migdal Insurance filed a 13G/A in October showing its stake at 10.1% of class, up from 9.5%. Menora Mivtachim filed a first-time 13G also in October, disclosing a 5.1% stake. None of these are activist 13D filings, all are passive, but the flurry of Israeli institutional activity in October points to concentrated domestic ownership at a moment when the stock is under meaningful selling pressure. Insider data reflects the August period, when the CEO and COO each sold above $1 million in shares at prices well above current levels. No buying is on record in the subsequent period.

Retail attention has spiked. The ORTEX Wikipedia views signal shows a z-score of 4.2 against CAMT's own 90-day history, the highest attention reading in that window, most likely reflecting the sharp price move and the Morgan Stanley downgrade rather than any fundamental catalyst. Peer moves on the week were broadly negative: NVMI fell 7.6%, FORM dropped 9.4%, and ONTO lost 5.5%, so CAMT's 12.8% weekly decline is at the sharp end but not entirely out of context for the group.

What to watch on November 10 is whether management addresses concentration risk in the Asian customer base and whether order trends in advanced packaging have held through the quarter, those are the two variables the Morgan Stanley downgrade explicitly challenged.